Continuous renal replacement therapy-related strategies to avoid colistin toxicity: A clinically orientated review

Blood Purification

Volumn 37, Issue 4, 2014, Pages 291-295

  Honoré, Patrick M ^a   Jacobs, Rita ^a   Joannes Boyau, Olivier ^d   Lochy, Stijn ^a   Boer, Willem ^c   Waele, Elisabeth De ^a   Gorp, Viola Van ^a   Regt, Jouke De ^a   Collin, Vincent ^b   Spapen, Herbert D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b Cliniques de l'Europe Site St Michel   (Belgium)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Acute kidney injury; Colistin; Colistin dosing; Continuous renal replacement therapy; Dialysis; Nephrotoxicity; Renal replacement therapy

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ANTICOAGULANT THERAPY; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; DISEASE ASSOCIATION; DRUG ADSORPTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; NEPHROTOXICITY; NEUROTOXICITY; PATHOPHYSIOLOGY; REVIEW; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; COMPLICATION; DEVICES; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY; PROCEDURES; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

EID: 84906011249     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000363495     Document Type: Review

References (25)

1. Spapen HD, Jacobs R, Van Gorp V, Troubleyn J, Honore PM: Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14.
2. Bergen PJ, Li J, Rayner CR, Nation RL: Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa . Antimicrob Agents Chemother 2006; 50: 1953-1958.
3. Couet W, Grégoire N, Marchand S, Mimoz O: Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012; 18: 30-39.
4. Yahav D, Farbman L, Leibovici L, Paul M: Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29.
5. Deryke CA, Crawford AJ, Uddin N, Wallace MR: Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54: 4503-4505.
6. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al: Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-1728.
7. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M: Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 2012; 18: 872-877.
8. Michalopoulos AS, Falagas ME: Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1: 30.
9. Spapen HD, Honore PM, Gregoire N, Gobin P, de Regt J, Martens GA, Pierard D, Couet W: Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. J Infect 2011; 63: 468-470.
10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL: Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
11. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE: Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56: 4241-4249.
12. Marchand S, Frat JP, Petitpas F, Lemaître F, Gobin P, Robert R, Mimoz O, Couet W: Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65: 1836-1837.
13. Markou N, Fousteri M, Markantonis SL, Zidianakis B, Hroni D, Boutzouka E, Baltopoulos G: Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67: 2459-2462.
14. Cho YS, Yim H, Yang HT, Hur J, Chun W, Kim JH, Lee BC, Seo DK, Park JM, Kim D: Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. Infection 2012; 40: 27-33.
15. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, Douglas A, Lipman J: Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-4815.
16. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H: Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-3436.
17. Honore PM, Jacobs R, Lochy S, De Waele E, Van Gorp V, De Regt J, Martens G, Joannes- Boyau O, Boer W, Spapen HD: Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 2013; 6: 107-111.
18. Lee J, Han S, Jeon S, Hong T, Song W, Woo H, Yim DS: Population pharmacokinetic analysis of colistin in burn patients. Antimicrob Agents Chemother 2013; 57: 2141-2146.
19. Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, Boer W, Verfaillie L, Spapen HD: Newly designed CRRT membranes for sepsis and SIRS - a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 2013; 59: 99-106.
20. Morimatsu H, Uchino S, Bellomo R, Ronco C: Continuous renal replacement therapy: does technique influence electrolyte and bicarbonate control? Int J Artif Organs 2003; 4: 289-296.
21. Kellum JA, Lameire N; KDIGO AKI Guideline Work Group: Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 2013; 17: 204.
22. Joannes-Boyau O, Honoré PM, Perez P, et al: High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39: 1535-1546
23. Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J: Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant 2012; 27: 967-973.
24. Honore PM, Joannes-Boyau O, Collin V, Boer W, Gressens B, Janvier G: Practical daily management of extra-renal continuous removal. Reanimation 2008; 17: 472-478.
25. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W: Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999; 56: 1578-1583.